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Introduction: Stimulation of mesenchymal stromal cells and adipose tissue-derived stromal cells (ASCs) with vascular
endothelial growth factor (VEGF) has been used in multiple animal studies and clinical trials for regenerative purposes.
VEGF stimulation is believed to promote angiogenesis and VEGF stimulation is usually performed under serum
deprivation. Potential regenerative molecular mechanisms are numerous and the role of contributing factors is
uncertain. The aim of the current study was to investigate the effect of in vitro serum deprivation and VEGF
stimulation on gene expression patterns of ASCs.
Methods: Gene expressions of ASCs cultured in complete medium, ASCs cultured in serum-deprived medium
and ASCs stimulated with VEGF in serum-deprived medium were compared. ASC characteristics according to
criteria set by the International Society of Cellular Therapy were confirmed by flow cytometry. Microarray gene
expressions were obtained using the Affymetrix HT HG-U133+ GeneChip®. Gene set enrichment analysis was
performed using the Kyoto Encyclopedia of Genes and Genomes and gene ontology terms. Transcription of
selected genes of interest was confirmed by quantitative PCR.
Results: Compared to ASCs in complete medium, 190 and 108 genes were significantly altered by serum deprivation
and serum deprivation combined with VEGF, respectively. No significant differences in gene expression patterns
between serum-deprived ASCs and serum-deprived ASCs combined with VEGF stimulation were found. Genes most
prominently and significantly upregulated by both conditions were growth factors (IGF1, BMP6, PDGFD, FGF9), adhesion
molecule CLSTN2, extracellular matrix-related proteins such as matricellular proteins SMOC2, SPON1 and ADAMTS12, and
inhibitors of proliferation (JAG1). The most significantly downregulated genes included matrix metalloproteinases (MMP3,
MMP1), and proliferation markers (CDKN3) and GREM2 (a BMP6 antagonist).
Conclusion: The decisive factor for the observed change in ASC gene expression proves to be serum starvation rather
than VEGF stimulation. Changes in expression of growth factors, matricellular proteins and matrix metalloproteinases in
concert, diverge from direct pro-angiogenic paracrine mechanisms as a primary consequence of the used protocol. In
vitro serum starvation (with or without VEGF present) appears to favour cardioprotection, extracellular matrix remodelling
and blood vessel maturation relevant for the late maturation phase in infarct healing.* Correspondence: Annette.Ekblond@regionh.dk
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Adipose tissue-derived stromal cells (ASCs) are being
clinically tested as regenerative therapy for patients with
ischaemic heart disease to improve myocardial perfusion
and to regenerate injured myocardium [1]. Though the
detailed mechanisms of action are as of yet not com-
pletely defined, the outcome of ASC therapy is pro-
moted by the vasculogenic or angiogenic abilities.
Aiming to enhance the efficacy of stem cell therapy, the
cells may be preconditioned with various substances to
prime them into more specialised functional patterns
prior to administration.
One of the most widely used preconditioning sub-
stances so far is vascular endothelial growth factor A-
165 (VEGF). Early in vitro and pre-clinical studies
suggested that VEGF, traditionally in combination
with serum deprivation, facilitated differentiation of
mesenchymal stromal cells (MSCs) and ASCs in an
endothelial direction [2-4], whereas current thinking
favours the notion of activation of resident cells
through secretion of cytokines and growth factors [5].
Potential regenerative molecular mechanisms are, how-
ever, numerous and the role of contributing factors is still
uncertain. On this basis, VEGF stimulation and serum
deprivation of MSCs has been used in clinical studies in-
cluding the double-blind, placebo-controlled trial MyStro-
malCell, which treats patients with chronic ischemic heart
disease with VEGF pre-stimulated and serum-deprived
ASCs [1,6,7].
In a recent study, we found a subtle priming only of
ASC differentiation in an endothelial direction when
ASCs were preconditioned with VEGF and serum
deprivation compared to standard culturing conditions
[8]. This raised the question whether VEGF precondi-
tioning and serum deprivation of ASCs induces angio-
genesis on a paracrine level by stimulating endothelial
cells and perhaps also induces modifications in extracel-
lular tissue components to facilitate improved microcir-
culation. As such, it is of great interest to elucidate the
molecular signature of ASCs per se and of ASCs that
have been preconditioned with VEGF and serum
deprivation to compare their constitutive expression pat-
terns with regard to angiogenesis and other tissue regen-
erative or stem cell-associated properties.
The aim of this study was to evaluate the gene ex-
pression profile of ASCs preconditioned with VEGF
and/or serum deprivation using culture conditions
similar to those applied in clinical stem cell trials [1].
With microarray analysis of ASCs under these condi-
tions it is possible to evaluate changes in gene expres-
sion in genes of importance for tissue reconstruction
and angiogenesis. We highlight the genes of relevance
for angiogenesis as VEGF is believed to promote
neovascularisation.Methods
Donors
Lipoaspirate was obtained from eight healthy donors
(two male and six female; mean age 41.5 years, range 21
to 57 years). All participants signed an informed con-
sent. This complied with the declaration of Helsinki and
the study was approved by the Ethical Committee, The
Capital Region of Denmark protocol no. H-3-2009-119.
Lipoaspirate preparation
Approximately 100 ml lipoaspirate was obtained from
each participant from the abdomen by liposuction under
local anaesthesia. The lipoaspirate was washed twice with
phosphate-buffered saline (PBS) pH 7.4 (GIBCO, Life
Technologies, Paisley, UK) to remove residual blood. The
adipose tissue was digested by incubation with Collagenase
NB 4 (SERVA Electrophoresis GmbH, Heidelberg, Germany)
dissolved in HBSS (2 mM Ca2+, GIBCO, Life Technologies)
at 37°C for 45 minutes under constant rotation. The collage-
nase was neutralized with complete medium (Dulbecco’s
modified Eagle's medium (DMEM), low glucose 1 g/l supple-
mented with 25 mM HEPES and L-Glutamin (GIBCO, Life
Technologies), 10% fetal bovine serum pharma grade (FBS;
GIBCO, Life Technologies), 1% penicillin/streptomycin
(GIBCO, Life Technologies)) and filtered through a
100-μm mesh (Cell Strainer, BD Bioscience, San Jose, CA,
USA). The remaining cells were centrifuged at 1,200 g for
10 minutes in RNase free tubes (BD Biosciences) at room
temperature, re-suspended and counted using Nucleo-
Counter® NC-100™ (Chemometec, Allerød, Denmark)
according to the manufacturer’s instructions.
Adipose tissue-derived stromal cell isolation and culture
Primary cell cultures of mononuclear cells were estab-
lished by seeding 4.5 × 106 cells/T75-flask (Nunc, Thermo
Scientific, Roskilde, Denmark) in complete medium. The
cells were incubated in standard conditions at 37°C in
humid air with 5% CO2. After two days in culture, cells
were washed with PBS (GIBCO, Life Technologies) to
remove non‐adhering cells, and thereafter complete
medium was added and changed every 3 to 4 days.
After approximately 1 week in culture, cells were detached
with 3 ml TrypLE® (TrypLE® Select, Gibco) for 10 minutes at
37°C and neutralized with 7 ml complete medium and
centrifuged at 300 g for 5 minutes, resuspended, counted on
NucleoCounter®, frozen 1 × 106 cells/1 ml FBS with
5% DMSO (WAK-Chemie Medical GmbH, Steinbach,
Germany) at −80°C in Nalgene® Mr.Frosty freezing container
(Sigma- Aldrich, St. Louis, MO, US) and transferred to liquid
nitrogen the following day for storage. When initiating
an experiment, ASCs at passage 1 were rapidly thawed
and seeded in T75-flasks with media changed the fol-
lowing day. When the cultures reached 80% confluence,
cells were passaged at 3 × 105 cells/T75-flask. ASC
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cording to The International Society for Cellular Therapy
minimal criteria for defining multipotent mesenchymal
stromal cells [9,10] (as described previously by Follin and
colleagues, 2013 [8]).
Serum deprivation and vascular endothelial growth factor
stimulation
Stimulation of cells followed a clinical protocol as previ-
ously described [1,8]. ASCs at passage 2 were cultured in
complete medium until 80% confluence, after which
medium was changed to either: 1) complete medium; 2)
serum‐deprived medium (DMEM with 2% FBS and 1%
penicillin/streptomycin (GIBCO, Life Technologies)); or 3)
VEGF stimulation medium consisting of serum‐deprived
medium with 50 ng/ml recombinant human VEGF‐A165
(rhVEGFA165, R&D Systems, Minneapolis, MN, US). Cells
were cultured for 1 week, and test media was renewed every
3days, afterwhich theywere harvested for further processing.
Nucleic acid extraction
After 1 week of cultivation in the three different media
cells were washed with PBS (GIBCO, Life Technologies),
detached with TrypLE® Select (GIBCO, Life Technologies),
and centrifuged for 5 minutes at 300 g. Then 350 μl lysis
buffer was added to the cell pellet from the Qiagen
RNeasy® Mini Kit (QIAGEN Hamburg GmbH, Hamburg,
Germany) and a 1 ml syringe (B. Braun Melsungen AG,
Melsungen, Germany) was used to mechanically lyse the
cells before resuming the Qiagen protocol. Finally, total
RNA was eluted with RNase-free water (5 Prime GmbH,
Hamburg, Germany). RNA purity and concentration was
measured using a NanoDrop® 1000 Spectrophotometer
(Thermo Scientific, Waltham, MA, US), and the eluate
was stored at –80°C until further analyses. RNA purity
was validated by absorbance ratios at 260 nm/280 nm and
protein contamination at A260/230. RNA integrity was
confirmed by RIN >8 using RNA Nano Chips (Agilent
Technologies, Santa Clara, CA, US) for the Agilent
2100 Bioanalyzer.
Microarray
RNA samples, eight from each of the three cultivation
conditions, were thawed and a final concentration of 33
ng/μl total RNA per sample was used for microarray
analysis. Samples were analysed separately. Expression
profiling was achieved using the Affymetrix GeneChip®
HT HG-U133+ 24-Array Plate (Affymetrix, Santa
Clara, CA, USA). Samples were labelled with Affyme-
trix Sensation Plus kit (Affymetrix) with 50 ng total
RNA as starting material. Biotin labelled cDNA (4 μg)
was used for the hybridization cocktail, and hybridization,
washing, staining and scanning were performed with an
Affymetrix Gene Titan instrument (Affymetrix). Microarraydata are available in the ArrayExpress database [11] under
accession number E-MTAB-3066.
Microarray analysis
Microarray analysis was performed using R 3.01 [12]
and Bioconductor [13]. The following gene expression
comparisons were made: 1) ASCs from serum deprived
medium versus ASCs from complete medium; 2) ASCs
from serum deprived medium versus ASCs from serum-
deprived medium stimulated with VEGF; and 3) ASCs
from complete medium versus ASCs from serum-
deprived medium stimulated with VEGF.
For each comparison the CEL files were imported into
R/Bioconductor and RMA (Robust Multi-array Average)
normalized. After this, all gene probes with a log2-fold
change below 0.5 were omitted. The expression levels of
each remaining gene were compared between the groups
using paired t-tests. P-values were adjusted using the
Benjamini and Hochberg procedure for multiple testing
corrections. Log2-fold change values were calculated for
each gene. Gene set enrichment analyses were made
using Webgestalt [14] for enriched gene-sets in gene
ontology (GO) categories and in enriched Kyoto
Encyclopedia of Genes and Genomes (KEGG) categories.
Genes of interest
Selection of gene categories of interest was partly ex-
plorative and partly predetermined. The different ap-
proaches involved were: 1) definition of groups using
Gene Enrichment Analysis linked with KEGG library
and GO terms as guiding templates for identifying un-
predicted and relevant up- and downregulated gene cat-
egories from the whole human genome analysis; and 2)
definition of predetermined categories relevant for ex-
pected response mechanisms. Predetermined categories
include angiogenesis, proliferation, and secretome.
Single genes of interest were selected based on an
elimination process of those genes that were at least two
times significantly (P < 0.05) up- or downregulated cor-
responding to a fold change >0.9. Three of the most
highly up- and downregulated genes were chosen for
confirmatory quantitative PCR.
Reverse transcription
The cDNA synthesis from total RNA was prepared using
AffinityScript (Stratagene, Agilent Technologies) in a fast
eight‐tube strip (0.1 ml, MicroAmp™, Applied Biosystems®,
Life Technologies, Paisley, UK) on ice. The total reaction
volume of 20 μl contained 0.5 μg RNA, 10 μl cDNA syn-
thesis master mix, 3 μl Oligo dT primer, 1 μl AffinityScript
RT RNase block enzyme mixture, and RNAase-DNAse
free water (5 Prime GmbH) to 20 μl total volume.
Reactions were performed with an initial stage of 25°C
for 5 minutes, 42°C for 45 minutes, and 95°C for 5
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tems®, Life Technologies). Following synthesis, cDNA was
stored in aliquots at –20°C.Confirmation by quantitative real-time PCR
Brilliant II SYBR®Green QPCR master mix with low
ROX (Agilent Technologies) was used with a total reac-
tion volume of 25 μl in 96-well optical reaction plates
(Agilent Technologies) with 5 μl cDNA diluted 1:5 in 1 ×
EDTA (QIAGEN Hamburg GmbH, Hamburg, Germany)
and subsequently 1:5 in RNAase-DNAse free water (5
Prime GmbH). The plates were sealed with optical plastic
caps (Agilent Technologies). Quantitative PCR was
performed with Mx3000 (Stratagene, AH-diagnostics,
Aarhus, Denmark) and the results were collected using
Mx3000 version 4.0 software for Windows (Stratagene,
AH-diagnostics). The reaction was initiated by heating to
95°C for 10 minutes, followed by 40 cycles of elongation
at 60°C for 1 minute and denaturation at 95°C for 30 sec-
onds. Primers used are shown in Table 1.Quantitative PCR analysis
Reference gene(s) for the quantitative PCR were selected
for the experimental conditions from a larger panel as
described previously [15] by taking into account effect of
donor- and treatment-variation on the reference genes.
Comparisons were made by the GenEx software (MultiD
Analyses AB, Goeteborg, Sweden) with the subprograms
geNorm and Normfinder. TATA-binding protein (TBP) and
Tyrosine 3/tryptophan 5-monooxygenase activation protein
(YWHAZ) in combination were the most suitable reference
genes for this set-up (Table 1). ΔΔCq normalization of
quantitative PCR data with 2ΔΔCq as the fold change
was used. Normalized data were analysed in SPSS
(Statistical Package for the Social Sciences IBM
Denmark, Holte, Denmark) with a paired t-test for
significant differences with a 95% confidence interval.Table 1 Reference genes and genes of interest for confirmati









Regulated genes of interest selected for confirmational quantitative PCR including r
Table presents full name, NCBI accession number and forward and reverse primer sResults
Microarray analysis
Adipose tissue-derived stromal cells from complete medium
compared to adipose tissue-derived stromal cells from
serum-deprived medium
A total of 615 probes, corresponding to 190 genes, were
found to be significantly up- or downregulated (P < 0.05).
Adipose tissue-derived stromal cells from complete medium
compared to adipose tissue-derived stromal cells from
serum-deprived medium stimulated with vascular
endothelial growth factor
The comparison demonstrated that 304 probes corre-
sponding to 108 genes differed significantly.
Adipose tissue-derived stromal cells from serum-deprived
medium compared to adipose tissue-derived stromal cells
from serum-deprived medium stimulated with vascular
endothelial growth factor
No significant differences were observed between the
two groups. An insignificant tendency was, however,
seen for a slightly greater fold change of genes expressed
in VEGF-stimulated ASCs than ASCs from serum-
deprived medium compared to ASCs from complete
medium. As a consequence, of the lack of statistical dif-
ferences in regulation of genes between serum-deprived
and VEGF-stimulated ASCs, final comparisons were
made between serum-deprived or VEGF-stimulated
ASCs versus control ASCs in complete medium only.
Some of the genes selected below only reached signifi-
cance in one of the two test conditions compared to
control cultures. Common to those genes is that regula-
tion moved in the same direction for both test condi-
tions but only reached a significant level in one.
Selection of genes of interest
Gene Enrichment Analysis linked with KEGG library
and GO terms and directed acyclic graphs showed aonal quantitative PCR









eference genes selected with consideration to donor- and treatment-variation.
equences.
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cellular region, particularly within the categories “extracel-
lular matrix” and “regulation of cell adhesion” (Figure 1).
Consequently, categories “adhesion” and “extracellular
matrix” were included as supplements to pre-determined
categories “angiogenesis”, “proliferation”, and “secretome”.
Significantly up- or downregulated genes, representing
chosen categories, as determined by GO terms, were se-
lected (Tables 2 and 3).
Selected genes were up to 5.5 times upregulated. A
5.5-times upregulation was calculated as 2 to the power
of the significant fold change (2FC). Hence, a 5.5-times
upregulation was derived from a positive fold change of
2.4564 equal to 22.4564. The following results are pre-
sented as x times up- or downregulations based on cal-
culated log2 measures.
Angiogenesis
The angiogenesis category proved to have only up- or
downregulated single genes that were shared by other
chosen categories according to GO terms. Bone morpho-
genetic protein 6 (BMP6) was found to be nearly four
times upregulated for both serum-deprived and VEGF-
stimulated ASCs compared to ASCs from complete
medium. Fibroblast growth factor 9 (FGF9) was also sig-
nificantly upregulated times two for the serum-deprived
ASCs as well as VEGF-stimulated ASCs, while Integrin
beta 3 (ITGB3) was two times downregulated in both.Figure 1 Directed acyclic graphs. Directed acyclic graphs (DAG) showed a
extracellular space particularly within the categories extracellular matrix and
activity (section of gene ontology analysis top 10 significantly regulated geAdhesion
A single gene in the adhesion category was significantly
upregulated for both comparison groups versus control.
That gene was Calsyntenin 2 (CLSTN2), which showed
a more than five times increase in expression. Junctional
adhesion molecule B (JAM2) was two times significantly
upregulated for serum-deprived cultures. Podocalyxin-
like protein 1 (PODX) and ITGB3 were approximately
two times downregulated with serum deprivation as well
as VEGF stimulation (Table 2).
Extracellular matrix
SPARC related modular calcium binding 2 (SMOC2) is
the highest upregulated gene in the extracellular matrix
(ECM) category, corresponding to 4.2 and 4.5 times, re-
spectively, in the serum-deprived and VEGF-stimulated
groups compared to control. Spondin 1/F-spondin
(SPON1) was two times upregulated in serum-deprived
cultures and three times upregulated in VEGF-stimulated
cultures. ADAM metallopeptidase with thrombospondin
type 1 motif (ADAMTS12), sarcoglycan delta (SGCD), der-
matopontin (DPT) and microfibrillar-associated protein 4
(MFAP4) were approximately two times upregulated in
both conditions. Protein tyrosine phosphatase receptor
type B (PTPRP) was significantly downregulated in VEGF-
stimulated cultures only, as opposed to transglutaminase 2
(TGM2) which was significantly downregulated in serum-
deprived cultures only. Matrix metallopeptidase 1 and 3strong representation of regulated genes employing proteins in the
protein binding comprising integrin binding and growth factor
nes; serum deprivation compared to 10% serum in culture medium).
Table 2 Expression levels for regulated genes according to primary gene ontology function
Serum-deprived VEGF-stimulated
Gene ID Gene name FC 2|FC| FC 2|FC|
Adhesion
CLSTN2 Calsyntenin 2 +2.375 +5.187 +2.456 +5.488
JAM2 Junctional adhesion molecule B +1.079 +2.112 NS NS
ITGB3 Integrin, beta 3 −0.709 −1.635 −1.040 −2.056
PODXL Podocalyxin-like protein 1 −1.126 −2.183 −1.066 −2.093
Extracellular matrix
SMOC2 SPARC related modular calcium binding 2 +2.059 +4.167 +2.185 +4.548
SPON1 Spondin 1, F-spondin, extracellular matrix protein +1.120 +2.174 +1.600 +3.039
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif +1.136 +2.198 +1.213 +2.318
SGCD Sarcoglycan delta +1.027 +2.038 +0.989 +1.985
DPT Dermatopontin +0.978 +1.970 +1.006 +2.008
MFAP4 Microfibrillar-associated protein 4 +0.950 +1.933 +0.964 +1.951
PTPRB Protein tyrosine phosphatase, receptor type, B NS NS −0.9992 −1.999
TGM2 Transglutaminase 2 −1.063 −2.090 NS NS
MMP3 Matrix metallopeptidase 3 −1.493 −2.816 −1.499 −2.826
COL13A1 Collagen, type XIII, alpha 1 −1.1227 −2.178 −0.9474 −1.028
MMP1 Matrix metallopeptidase 1 −2.139 −4.405 NS NS
Groups defined by Gene Enrichment Analysis linked with Kyoto Encyclopedia of Genes and Genomes library and gene ontology terms. Fold changes (FC) and
consequently calculated amount of up (+) or down (−) regulation (2|FC|) of significant genes (P < 0.05) compared to adipose tissue-derived stromal cells (ASCs) in
complete medium are listed for vascular endothelial growth factor (VEGF)-treated and serum-deprived ASCs FC >0.9. Most of the regulated genes are shared
between groups, but have been assigned to the primary group for the sake of clarity. NS, not significant.
Tratwal et al. Stem Cell Research & Therapy  (2015) 6:62 Page 6 of 12(MMP1 and MMP3) were downregulated 4.4 and 2.8
times, respectively, significantly only for serum-deprived
cultures. Transcription of collagen 13 alpha 1 (COL13A)
was also downregulated (Table 2).Secretome
The secretome category presented five upregulated
growth factor genes: insulin-like growth factor 1 (IGF1),
BMP6, FGF9, hepatocyte growth factor (HGF) and
platelet-derived growth factor D (PDGFD). They were all
upregulated two to three times in both conditions, ex-
cept for HGF being only significantly upregulated in
VEGF-stimulated cultures. The growth factor transform-
ing growth factor beta1 (TGFB1) was two times down-
regulated. TLR4 interactor with leucine-rich repeats
(TRIL) was upregulated three times for serum-deprived
cultures and four times for VEGF-stimulated cultures.
Proprotein convertase subtilisin/kexin type 5 (PCSK5)
was 2.1 and 2.8 times upregulated for the serum-
deprived and VEGF-stimulated groups. Gremlin 1 and 2,
DAN family of BMP antagonists (GREM1 and GREM2)
were both downregulated, GREM2 most substantially
with 5.0 and 5.4 times downregulation in serum-
deprived and VEGF-stimulated cultures, respectively.
Membrane metallo-endopeptidase (MME) was downreg-
ulated two times (Table 3).Proliferation
Overall, three genes were significantly upregulated in the
GO-defined proliferation category and four genes were
significantly downregulated. Unique to the proliferation
category was sprouty homolog 1, antagonist of FGF sig-
naling (SPRY1) upregulated 2.8 times in serum-deprived
ASCs. TEK tyrosine kinase, endothelial (TEK) was two
times upregulated, also only significantly for serum-
deprived ASCs. Jagged-1 (JAG1) was significantly upreg-
ulated in both conditions 1.7 and 1.9 times, respectively.
In this category, cyclin-dependent kinase inhibitor 3
(CDKN3) was downregulated 3.2 times (serum-deprived
ASCs) and 2.6 times (VEGF-stimulated ASCs), along
with antigen identified by monoclonal antibody Ki-67
(MKI167), cyclin B1 (CCNB1), heme oxygenase (decycling)
1 (HMOX1) and TPX2, microtubule-associated (TPX2)
(all downregulated approximately two times; for MKI67
and CCNB1 only significantly so for VEGF-stimulated and
serum-deprived cultures, respectively (Table 3)).
Confirmational quantitative PCR
Quantitative PCR results confirmed microarray analysis
(Figure 2). SMOC2 was shown to be four-fold upregu-
lated by both methods for VEGF-stimulated or serum-
deprived ASCs compared to control. BMP6 was 3.7 and
3.2 times upregulated on quantitative PCR for serum-
deprived and VEGF-stimulated ASCs compared to 3.7
Table 3 Expression levels for regulated genes according to primary gene ontology function
Serum-deprived VEGF-stimulated
Gene ID Gene name FC 2|FC| FC 2|FC|
Proliferation
SPRY1 Sprouty homolog 1, antagonist of FGF signaling +1.493 +2.815 NS NS
TEK TEK tyrosine kinase, endothelial +1.024 +2.033 NS NS
JAG1 Jagged 1 +0.8085 +1.751 +0.9621 +1.948
CDKN3 Cyclin-dependent kinase inhibitor 3 −1.668 −3.178 −1.386 −2.614
MKI67 Antigen identified by monoclonal antibody Ki-67 NS NS −1.222 −2.333
CCNB1 Cyclin B1 −1.324 −2.504 NS NS
HMOX1 Heme oxygenase (decycling) 1 −1.047 −2.066 −0.969 −1.957
TPX2 TPX2, microtubule-associated NS NS −1.042 −2.058
Secretome
IGF1 Insulin-like growth factor 1 +1.963 +3.897 +1.999 +3.998
BMP6 Bone morphogenetic protein 6 +1.902 +3.738 +1.980 +3.944
TRIL TLR4 interactor with leucine-rich repeats +1.691 +3.229 +2.005 +4.013
PCSK5 Proprotein convertase subtilisin/kexin type 5 +1.091 +2.131 +1.480 +2.791
FGF9 Fibroblast growth factor 9 +1.044 +2.061 +0.871 +1.829
HGF Hepatocyte growth factor NS NS +0,9719 +1,961
PDGFD Platelet derived growth factor D +1.048 +2.067 +0.900 +1.866
GREM1 Gremlin 1, DAN family BMP antagonist −0.960 −1.946 −0.918 −1.891
TGF1 Transforming growth factor beta1 −0.962 −1.965 −0.908 −1.877
MME Membrane metallo-endopeptidase −1.322 −2.500 −1.432 −2.699
GREM2 Gremlin 2, DAN family BMP antagonist −2.326 −5.019 −2.425 −5.368
Pre-defined groups. Fold changes (FC) and consequently calculated amount of up (+) or down (−) regulation (2|FC|) of significant genes (P < 0.05) compared to
adipose tissue-derived stromal cells (ASCs) in complete medium are listed for vascular endothelial growth factor (VEGF)-treated and serum-deprived ASCs FC >0. 9.
NS, not significant.
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for IGF1 were less consistent with 2.8 (serum-deprived
ASCs) and 1.8 (VEGF-stimulated ASCs) times upregula-
tion on quantitative PCR with nearly four times upregula-
tion for both groups on microarray. The ITGB3 2.5 times
downregulation by serum deprivation or VEGF stimula-
tion on quantitative PCR confirmed the two times down-
regulation of this gene on microarray. MMP3 was shown
to be downregulated 3.3 times by quantitative PCR and
2.8 times by microarray analysis, while MMP1 was also
downregulated in both analyses but not to the same extent
observed with quantitative PCR (3.3 times for both
groups) as with microarray (4.4 times).
Discussion
ASCs have therapeutic regenerative potential for patients
with ischaemic heart disease as well as for multiple other
degenerative diseases. In vitro preconditioning of ASCs
with VEGF-stimulation and serum-deprivation prior to
administration is applied pursuing enhanced efficacy of
treatment in an angiogenic direction. VEGF stimulation
is believed to promote angiogenesis, but regenerative
molecular mechanisms are numerous and currentcomparative analysis of the gene profile of VEGF-
stimulated and serum-deprived ASCs have revealed
other potentially contributing factors. Gene Enrichment
Analysis linked with KEGG library and GO terms point
towards a large regulation of cellular components in-
volved in the extracellular space and thereby cell-to-cell
or cell-to-ECM communication. These include cytokines
and growth factors, adhesion molecules and a variety of
ECM constituents.
Surprisingly, our data showed that serum deprivation
of ASCs rather than VEGF stimulation was the decisive
factor for the observed change in ASC gene expression
in vitro.
Interpreting this observation, the contribution from
endogenous VEGF production is a potential confounder
in case the endogenous production exceeds the dose
used during VEGF stimulation. Our laboratory has iden-
tified that the endogenous production of VEGF from
ASCs in the present protocol does take place (unpub-
lished data). Microarray analyses showed that transcrip-
tion of VEGF was significantly upregulated with serum
deprivation and VEGF stimulation in the present study.
Fold change was below our cut-off value and was
Figure 2 mRNA expression levels by quantitative PCR for selected genes
of interest. Quantitative PCR results for three up- and downregulated
genes of vascular endothelial growth factor (VEGF)-stimulated or
serum-deprived adipose tissue-derived stromal cells compared to
control correspond with significant microarray data. ***P < 0.001,
**P < 0.01, **P < 0.05. N = 3. BMP6, Bone-morphogenic protein;
IGF1, insulin-like growth factor 1; ITGB3, integrin-beta 3; MMP,
Matrix metalloproteinase; SE, standard error of the mean; SMOC2,
SPARC-related modular calcium binding 2.
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but it pointed out that endogenous VEGF production
did take place and was stimulated by serum starvation,
as in agreement with observations made by Chua and
colleagues [16]. The production of endogenous VEGF in
our ASC cultures is, however, in the lower picogram/ml
range and is therefore considered to play an insignificant
role compared to the 50 ng/ml exogenous VEGF added
during VEGF stimulation.
The present microarray analyses do not reveal the
level of VEGF receptors in our ASC cultures, nor do
they reveal receptor ligand binding. We merely conclude
that test circumstances do not significantly change the
transcription of VEGF receptors. In other words, results
do not explain why VEGF is not decisive. However, as
previously discussed by Follin and colleagues [8] and
Chua and colleagues [16], we suggest that VEGF needs
to be part of a more complex stimulation protocol in
order to exercise sufficient effectiveness.
Serum deprivation proves to have an impact on the
ASC secretome and interaction with the extracellular
environment. We identified a significant upregulation of
growth factors IGF1 (nearly four times upregulated),
PDGFD and FGF9 (two times) which corresponds with
other microarray studies performed on bone marrow-
derived stem cells where IGF1 was highly upregulated in
long-term serum-deprived cells [17]. IGF-1 secreted
from ASCs is known to initiate cardioprotective actionsinhibiting cardiomyocyte apoptosis in vitro as well as
in vivo [18,19]. FGF9 (also known as heparin binding
growth factor HBGF) is a member of the fibroblast
growth factor family. FGF family members possess broad
cell survival activities, and are involved in a variety of
biological processes, including morphogenesis and tissue
repair [20]. Platelet-derived growth factor, PDGFD, a
newly recognised member of the PDGF family, has re-
cently been shown to promote fibrogenesis of cardiac fi-
broblasts. PDGFD elevates cardiac fibroblast proliferation,
myofibroblast differentiation, and type I collagen secre-
tion; it regulates matrix metalloproteinase activities and
TGF-β pathways and has a significant effect on ECM
turn-over [21].
We also found that BMP6 was nearly four times up-
regulated in conditioned ASCs and we identified a five
times downregulation of GREM2, a BMP-6 antagonist.
BMP-6, along with the other members of the BMP fam-
ily, has diverse biological activities in various systems,
generally stimulating differentiation and inhibiting pro-
liferation. In concert, BMP6 and GREM2 play roles in
organogenesis and tissue differentiation. During embry-
onic development, GREM2 is required for atrial differen-
tiation along with establishment of cardiac rhythm [22].
The blocking of BMP inhibits differentiation and pro-
motes the expansion of stem cells [23].
It is empirical that serum starvation inhibits prolifera-
tion in cell cultures. In fact, the rationale behind the
used cultivation protocol is that serum starvation com-
bined with VEGF stimulation favours MSC and ASC
endothelial differentiation at the expense of proliferation
[2,4]. In a previous publication we showed that ASC
differentiation towards endothelium requires a more
complex protocol than serum deprivation combined
with VEGF stimulation only [8]. In the present study
we hypothesised that the present cultivation protocol
would favour secretion of pro-angiogenic factors and
thereby stimulate angiogenesis by paracrine mecha-
nisms. GO analyses of microarray data, however, do not
show any direct augmented pro-angiogenic paracrine
activity as a consequence of the used protocol. The ob-
served increase in BMP6 production does correlate
with the desired inhibition of proliferation; however,
BMP6 production is known for its involvement in car-
diovascular development stimulating cardiomyocyte
differentiation rather than endothelial [24]. Stimulation
of cardiomyocytes is further supported by the observed
upregulation in the protein Jagged-1. Jagged-1 is in-
volved in cell-cell signalling, and murine MSCs are
known to promote proliferation of cardiomyocytes by
Jagged1:Notch1 signalling [25].
In concert the observed changes in the ASC secretome
during serum starvation suggest that used pre-stimulation
protocol activates signals that favour cardiac repair by
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proliferation, cell survival in general, and activation of fi-
broblasts favouring ECM turnover.
In general, changes in paracrine activity induce dy-
namic changes in ECM composition, regulating the in-
flammatory, fibrogenic, and angiogenic pathways at
different stages of regeneration in the infarcted heart.
Matricellular proteins induced following tissue injury as-
sociate with growth factors and cytokines, and modulate
cell-cell and cell-matrix interactions. Matricellular pro-
teins play no structural role, but modify cell function by
regulating ECM assembly, adhesion, ECM protease ac-
tivity and growth factor signalling, and as such are be-
lieved to play an important role in the regulation of
cardiac repair [26]. Matricellular proteins promote de-
adhesion, creating an intermediate cellular adhesive state
that activates survival signals [27]. Matricellular proteins
include the SPARC (secreted protein acidic and rich in
cysteine) family and thrombospondins. SPARC has
proved to be important for organisation of the scar and
maturation of collagen after myocardial infarction; over-
expression of SPARC protects against cardiac dilatation
[28]. A member of the SPARC family has been identified
as secreted modular calcium-binding protein 2 (SMOC-2)
[29]. SMOC-2 potentiates the angiogenic effects of growth
factors. Overexpression of SMOC-2 in endothelial cells
synergises with VEGF or bFGF to stimulate DNA synthe-
sis, migration, and tube formation [30]. Thrombospondin
1, an inhibitor of angiogenesis and cell proliferation, was
downregulated in such SMOC-2-overexpressing endothe-
lial cells. In our setting the expression of Thrombospondin
1 was insignificantly affected by the treatment and, there-
fore, not directly correlated with SMOC-2 expression
(data not shown).
SPON1 (F-Spondin or vascular smooth muscle cell
growth-promoting factor) belongs to the thrombospondins
and contains the thrombospondin type 1 repeat (TSR)
involved in matrix organisation and cell-cell interactions
[31,32]. F-Spondin inhibits angiogenesis, namely VEGF- or
bFGF-stimulated migration of HUVECs (Human Umbilical
Vein Endothelial Cells), and specifically ITGB3-mediated
endothelial cell spreading [33]. In turn, SPON1 stimulates
proliferation of smooth muscle cells in the vascular wall.
Thus, inhibition of angiogenesis is followed by the growth
of smooth muscle cells and the maturation of vessels [33].
Culturing ASCs with VEGF and serum deprivation we
have identified that SMOC-2 is more than four times
upregulated and F-Spondin is two (serum-deprivation)
to three times (VEGF-stimulation) upregulated. Both
proteins are involved in matrix regulation; however, pos-
sibly with opposing effects on angiogenesis and endothe-
lial behaviour. This underscores the importance and
complexity of cell-ECM interactions and the need to
examine these matters more thoroughly. In concert,observations indicate that VEGF stimulation and serum
deprivation does affect regeneration and angiogenesis,
but indirectly so, by modulating ECM, generating or
preventing a permissive environment.
SMOC-2 has recently been identified as a stem cell
marker in the intestinal crypt base cells. Switching the
status of active WNT/inactive BMP pathways of human
intestinal epithelial crypt cells (from the fetal intestine)
triggers a conversion towards a stem cell-like state with
expression of genes including SMOC-2 [34]. MSCs cul-
tured in hypoxic conditions (5% O2) display an enhanced
expression of genes involved in plasticity with the most
highly upregulated gene in this group being SMOC-2
[35]. While culture in hypoxia maintains MSCs in a mul-
tipotent undifferentiated state, they express more adhe-
sion and ECM molecules, including SMOC-2, than
MSCs cultured in normoxic conditions [35]. It appears
that culturing ASCs with serum deprivation mimics lim-
ited blood supply and thereby hypoxia as well as in vivo
ischaemic conditions. The observed increase in SMOC-2
expression suggests that our protocol favours stemness.
SPARC along with other matricellular proteins are
known to reorganise actin fibres and disassembly of focal
adhesion molecules to facilitate cell migration when a
cell undergoes transformation from a strong to an inter-
mediate adhesive state in response to injury or other
types of tissue remodelling [27]. The soluble SPARC
protein was originally found to induce MMP-1, MMP-3,
and MMP-9 activity in synovial fibroblasts [36]. MMP-1
promotes collagen breakdown in the infarcted area of
the heart and MMP-3 is an upstream activator of MMP-
9, which can break down scar tissue and permeabilise
the ECM to allow for revascularisation in an acute in-
farct [37,38]. Furthermore, it has been suggested that
MMP inhibition protects from adverse tissue remodel-
ling [39].
We identify a noticeable downregulation of MMP 1
and MMP3 in ASCs cultured with serum deprivation,
indicating a stabilising effect on the ECM. In addition
we find that ADAMTS12, a metalloproteinase with
thrombospondin motifs, is two times upregulated.
ADAMTS12 binds to the ECM and has been shown to
sequester VEGF, leading to inhibition of endothelial pro-
liferation [40,41]. ADAMSTS12 is upregulated in bone
marrow-derived MSCs with increasing in vitro passages
and is inversely associated with growth and proliferation
in these cells [42].
Normal wound healing as well as myocardial regener-
ation is initiated by an inflammatory phase followed by a
proliferative phase characterised by ECM deposition and
angiogenesis. The maturation phase follows, represented
by matrix stabilisation and vascular maturation. The ob-
servation that ASCs stimulated with VEGF and serum
deprivation downregulate collagen turnover, ECM
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cells and revascularisation, but stimulates smooth
muscle cells in the vascular wall, indicate that the used
pre-stimulation protocol promotes cells that contribute
to the maturation phase.
We find pronounced upregulation in transcription of
adhesion molecules Calsyntenin-2 (CLSTN2) and junc-
tional adhesion molecule JAM-2. CLSTN2 belongs to
the cadherins and a family of postsynaptic membrane
proteins, and JAM2 has been associated with endothelial
junctions and leukocyte-endothelial interactions only.
The significance of these adhesion molecules with regard
to ASC-mediated regeneration remains elusive, and
presently only lends support to the idea that cell-cell in-
teractions are important for ASC mechanisms of action.
Transcription of adhesion molecules such as integrin
beta 3 and Podocalyxin-like protein 1 (PODXL, a sialo-
mucin) was decreased, potentially affecting cell-ECM in-
teractions. From studies with cancer cells it is known
that silencing of PODXL reduces migration and inter-
action with collagen. MSCs are also known to express
PODXL, and the level of expression has been shown to
correlate with MSC clonogenicity as well as the ability
to differentiate and migrate [43,44].
The observed upregulation in the transcription of
Sarcoglycan delta (SGCD), part of the dystrophin-
glycoprotein complex muscle-specific proteins exclu-
sively expressed in the skeletal and cardiac muscles and
creating a link between the cell cytoskeleton and the
ECM, supports the theory that the chosen pre-
stimulation protocol mimics an environment in favour
of cardiomyocyte development [45].
The significantly up- and downregulated proliferative
markers all reflect the observed inhibition in prolifera-
tion with the used pre-stimulation protocols. Cellular
changes, including ASC proliferation, are regulated by
the growth factor activated mitogen-activated protein
kinase (MAPK) signalling pathway. Expression of SPRY1,
which is an inhibitor of FGF signalling and thereby
MAPK signalling, is upregulated in serum-deprived
ASCs, correlating with the observed decrease in prolifer-
ation. In endothelial cells, upon FGF receptor and VEGF
receptor activation, SPRYs are known to translocate to
the plasma membrane and inhibit proliferation [46]. In
addition, cyclin-dependent kinase inhibitor 3 (CDKN3)
and Cyclin B1(CCNB1), which are regulatory proteins
that are essential for commitment of cells to mitosis, are
downregulated in pre-stimulated ASCs. In essence the
observed changes in proliferation markers image our test
culture circumstances where the restricted conditions
without serum halt proliferation compared to control
conditions.
The regenerative effects of transplanted cells are al-
ways the sum of interactions with the surroundingtissue. The full consequence of the used in vitro priming
of cells upon delivery into a multifactorial in vivo envir-
onment remains to be shown. Thorough in vitro charac-
terisation of the cell products used in the clinic is,
however, a valuable tool for interpretation of pre-clinical
and clinical results. Where the shown effects of the
present pre-stimulation protocol upon ASC transcrip-
tional activity are tangible the projected consequences of
these effects upon in vivo delivery are at this point to be
regarded as hypothesis generating.
Conclusion
ASCs are used as an experimental regenerative therapy
for patients with ischaemic heart disease to improve
myocardial perfusion and to regenerate injured myocar-
dium. Aiming to enhance the efficacy of stem cell ther-
apy, different regimes of in vitro preconditioning prior
to administration are examined. We have elucidated the
molecular signature of ASCs that have been precondi-
tioned with serum deprivation and VEGF stimulation.
We show that serum deprivation is the decisive factor
and that serum deprivation of ASCs has an important
impact on the microenvironment by the ECM compo-
nents and signalling molecules that they secrete. Given
that the genes regulated upon serum deprivation in
ASCs are primarily involved in stabilisation of ECM,
fibrogenesis, inhibition of angiogenesis, maturation of
vessels, differentiation and protection of cardiomyocytes,
we hypothesise that these ASCs will exert their effect on
cardiac repair by regulating the dynamic cellular and
ECM events during the late maturation phase in infarct
healing.
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